What is Zacks Research's Estimate for Surmodics Q2 Earnings?

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Equities research analysts at Zacks Research dropped their Q2 2026 earnings per share (EPS) estimates for shares of Surmodics in a research report issued on Tuesday, May 27th. Zacks Research analyst D. Dey now forecasts that the company will post earnings per share of $0.01 for the quarter, down from their prior estimate of $0.02. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics' Q3 2026 earnings at $0.01 EPS, Q4 2026 earnings at $0.08 EPS, Q1 2027 earnings at $0.01 EPS and FY2027 earnings at $0.29 EPS.

Surmodics (NASDAQ:SRDX - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.07). Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%. The business had revenue of $28.09 million for the quarter, compared to the consensus estimate of $32.23 million.

Other equities research analysts also recently issued reports about the stock. Needham & Company LLC restated a "hold" rating on shares of Surmodics in a research report on Wednesday, April 30th. Wall Street Zen began coverage on Surmodics in a research note on Monday, February 3rd. They issued a "hold" rating for the company. Finally, Lake Street Capital upgraded Surmodics from a "hold" rating to a "buy" rating and set a $43.00 price objective on the stock in a research report on Friday, March 7th.

Surmodics Stock Performance

Shares of NASDAQ SRDX traded up $0.10 during mid-day trading on Thursday, reaching $29.12. 20,753 shares of the company were exchanged, compared to its average volume of 260,038. The stock has a market capitalization of $416.32 million, a P/E ratio of -28.83 and a beta of 1.32. The company has a quick ratio of 4.29, a current ratio of 5.45 and a debt-to-equity ratio of 0.26. The company's 50-day simple moving average is $28.71 and its 200-day simple moving average is $33.50. Surmodics has a twelve month low of $26.00 and a twelve month high of $42.44.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in SRDX. Millennium Management LLC raised its position in shares of Surmodics by 0.4% in the fourth quarter. Millennium Management LLC now owns 120,344 shares of the company's stock valued at $4,766,000 after buying an additional 509 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Surmodics by 1.8% in the 1st quarter. Principal Financial Group Inc. now owns 36,699 shares of the company's stock valued at $1,120,000 after acquiring an additional 638 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Surmodics by 4.4% during the 4th quarter. Rhumbline Advisers now owns 20,250 shares of the company's stock valued at $802,000 after acquiring an additional 861 shares during the period. Legal & General Group Plc lifted its position in shares of Surmodics by 34.2% during the 4th quarter. Legal & General Group Plc now owns 3,452 shares of the company's stock valued at $137,000 after acquiring an additional 880 shares during the period. Finally, Salem Investment Counselors Inc. grew its holdings in shares of Surmodics by 1.1% during the 1st quarter. Salem Investment Counselors Inc. now owns 114,950 shares of the company's stock worth $3,509,000 after purchasing an additional 1,200 shares in the last quarter. Institutional investors and hedge funds own 96.63% of the company's stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).